Peachtree Investment Partners’s AbbVie ABBV Stock Holding History

Peachtree Investment Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$424K	Sell	1,951 -175	-8%	-$38.8K	0.16%	58
2025 Q4	$486K	Buy	2,126 +175	+9%	+$39.9K	0.16%	53
2025 Q3	$452K	Sell	1,951 -231	-11%	-$47K	0.16%	55
2025 Q2	$405K	Buy	2,182 +127	+6%	+$23.6K	0.15%	60
2025 Q1	$430K	Buy	+2,055	New	+$400K	0.17%	53
2024 Q4	–	Sell	-1,228	Closed	-$243K	–	115
2024 Q3	$243K	Buy	+1,228	New	+$229K	0.09%	79
2024 Q1	–	Sell	-1,699	Closed	-$263K	–	99
2023 Q4	$263K	Buy	1,699 +14	+0.8%	+$2.04K	0.11%	76
2023 Q3	$251K	Sell	1,685 -272	-14%	-$39.9K	0.13%	69
2023 Q2	$264K	Sell	1,957 -1,111	-36%	-$163K	0.12%	77
2023 Q1	$489K	Sell	3,068 -3,595	-54%	-$550K	0.31%	48
2022 Q4	$1.08M	Buy	6,663 +3,647	+121%	+$559K	0.66%	29
2022 Q3	$405K	Sell	3,016 -1,682	-36%	-$241K	0.27%	45
2022 Q2	$719K	Sell	4,698 -455	-9%	-$69.5K	0.45%	36
2022 Q1	$835K	Buy	5,153 +2,865	+125%	+$416K	0.38%	43
2021 Q4	$310K	Buy	+2,288	New	+$270K	0.13%	70

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Peachtree Investment Partners's ABBV Position: Q1 2026 in Review

Peachtree Investment Partners reduced its AbbVie (ABBV) stake by 8.2% in Q1 2026, selling an estimated $38.8K and leaving 1,951 shares worth $424K. The position accounts for 0.16% of the portfolio, ranked #58.

Peachtree Investment Partners first reported a position in ABBV in Q4 2021 and has held it in 15 quarters since. The position peaked at $1.08M in Q4 2022. 4,079 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Peachtree Investment Partners held 1,951 shares of AbbVie worth $424K as of Q1 2026.
Peachtree Investment Partners sold 175 AbbVie shares in Q1 2026, an estimated $38.8K.
AbbVie made up 0.16% of Peachtree Investment Partners's portfolio in Q1 2026, its #58 holding.
Peachtree Investment Partners first reported a position in AbbVie in Q4 2021 and has held it in 15 quarters since.
Peachtree Investment Partners's AbbVie position peaked at $1.08M in Q4 2022.
4,079 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Peachtree Investment Partners's 13F filing for Q1 2026, filed 8 May 2026.